

FORM 51-102F3

MATERIAL CHANGE REPORT

Item 1 *Name and Address of Company*

Seashore Organic Medicine Inc. ("the **Issuer**")
Suite 101, 5682 Wharf Street,
Sechelt, BC V0N 3A0

Item 2 *Date of Material Change*

October 6, 2014

Item 3 *News Release*

A news release was issued and disseminated on October 6, 2014 and the news release was filed on SEDAR.

Item 4 *Summary of Material Change(s)*

The Issuer has announced that further to a letter of intent entered into on September 5, 2014, with Cannevert Therapeutics Ltd., the parties have agreed to extend the date by which the obligations set out in the letter of intent must be completed, including the signing of a definitive agreement, to October 9, 2014.

Item 5 *Full Description of Material Change*

See news release attached as Schedule "A"

Item 6 *Reliance on subsection 7.1(2) of National Instrument 51-102*

Not applicable.

Item 7 *Omitted Information*

None.

Item 8 *Executive Officer*

Leonard Werden, President & CEO
Telephone: +1.604.885.5500
Email: info@seashoremachine.com

Item 9 *Date of Report*

October 7, 2014



Seashore Organic Medicine

SCHEDULE "A"

SEASHORE ORGANIC MEDICINE INC. MUTUALLY EXTENDS LETTER OF INTENT

October 6, 2014, Vancouver, B.C. – Seashore Organic Medicine Inc. (the "Company") (CSE: SOM) and Cannevert Therapeutics Ltd. ("CTL") announced today that further to the press release dated September 8, 2014 announcing the execution of a letter of intent ("LOI") by SOM and CTL, the parties have agreed to extend the date by which the obligations set out in the LOI, including the signing of a Definitive Agreement must be completed, to October 9, 2014. The transaction remains subject to requisite approvals and the execution of a Definitive Agreement.

About the Company

The Company was formed to become a producer of medical marihuana under the MMRP. The Company has applied to become a licensed producer under the MMRP program. The Company is based out of Sechelt, on the Sunshine Coast of British Columbia. The Company and board of advisors have a diverse range of experience and multi-industry expertise.

On behalf of the Board of Directors
SEASHORE ORGANIC MEDICINE INC.

"Leonard Werden"
Leonard Werden
CEO

Further information about the Company is available on our website at www.seashoremachine.com or under our profile on SEDAR at www.sedar.com and on the CSE website at www.thecse.com.

Investor and Public Relations Contact

Seashore Organic Medicine Inc.
Leonard Werden
Chief Executive Officer
Telephone: +1.604.885.5500
Email: info@seashoremachine.com
Website: www.seashoremachine.com

The CSE has not reviewed, nor approved or disapproved the content of this press release.

Forward-Looking Information

This press release may include forward-looking information within the meaning of Canadian securities legislation concerning the business of the Company. Forward-looking information is based on certain key expectations and assumptions made by the management of the Company, including future plans for development of technologies by the Company. Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. The Company disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.